RNA241115P27000
- 0.00
- 0.000.00%
Avidity Biosciences Newsroom
A Quick Look at Today's Ratings for Avidity Biosciences(RNA.US), With a Forecast Between $51 to $75
Avidity Biosciences Is Maintained at Buy by Chardan Capital
Avidity Biosciences Analyst Ratings
TD Cowen Maintains Avidity Biosciences(RNA.US) With Buy Rating, Raises Target Price to $78
TD Cowen Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $56
A Quick Look at Today's Ratings for Avidity Biosciences(RNA.US), With a Forecast Between $56 to $75
Analysts' Top Healthcare Picks: DocGo (DCGO), Avidity Biosciences (RNA)
Analysts Conflicted on These Healthcare Names: LivaNova (LIVN), Johnson & Johnson (JNJ) and Avidity Biosciences (RNA)
Avidity Biosciences Price Target Announced at $59.00/Share by Goldman Sachs
Goldman Sachs Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $59
Cantor Fitzgerald Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $96
Cantor Fitzgerald Reaffirms Their Buy Rating on Avidity Biosciences (RNA)
Avidity Biosciences Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Avidity Biosciences, Maintains $96 Price Target
Wells Fargo Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $75
Barclays Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $63
Barclays Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $63
Analysts' Top Healthcare Picks: Addex Therapeutics (ADXN), Avidity Biosciences (RNA)
Avidity Biosciences Price Target Cut to $53.00/Share From $54.00 by Evercore ISI Group
Avidity Biosciences Analyst Ratings